Moreover, the treatment of metastatic melanoma has advanced little in the last three decades, with ipilimumab (a monoclonal antibody targeting CTLA-4 on T cells) and the BRAF inhibitor, vemurafenib, the only treatments to show an increase in overall survival and an extension of survival time, respectively. This evidence concerns the gene BRAF and metastatic melanoma.